SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsMolecular Targeted Therapeutics

PUBLISHER: Visiongain | PRODUCT CODE: 2151278

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2151278

Global Antibody Drug Conjugates Contract Manufacturing Market Report 2026-2036

PUBLISHED:
PAGES: 326 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5872.50
PDF (Team License - Up to 6 Users)
USD 6952.50
PDF (Site License)
USD 8167.50
PDF (Enterprise License - Includes Free Datasets)
USD 10320.75

Add to Cart

Description

Table of Contents

List of Tables

This report provides a comprehensive analysis of the market including market size, growth drivers, competitive positioning, and revenue forecasts across linker, service, condition, and scale of operation segments.

Expanding Clinical and Commercial ADC Pipeline

The continued expansion of the antibody-drug conjugate pipeline is creating sustained demand for specialised contract development and manufacturing services. An ADC programme requires coordinated control of three distinct components - the monoclonal antibody, linker and highly potent payload - followed by conjugation, purification, formulation and analytical characterisation. Manufacturing requirements become more demanding as programmes advance, with late-stage candidates requiring larger GMP batches, validated processes, stability programmes and comprehensive regulatory documentation.

Approved products then create recurring demand for reliable commercial supply and consistent product quality. Many developers do not maintain dedicated high-potency handling and bioconjugation infrastructure internally. This is strengthening demand for specialist providers and integrated CDMOs that can support individual process components or manage an ADC programme across development, clinical supply and commercial manufacturing.

Report Scope and Data Coverage

  • Global ADC contract manufacturing market analysis
  • Revenue forecasts to 2036 with annual growth estimates
  • Segment-level modelling across linker, service, condition, and scale of operation
  • Regional and national market forecasts across five regions and 14 leading national markets
  • Competitive intelligence on 20 leading companies

Includes both quantitative forecasting and qualitative strategic analysis covering technology, competition, trade dynamics, and supply chain developments.

Our 300-page report provides 122 tables and 158 charts/graphs.

Segmentation Framework

By Linker

  • Cleavable Linker
  • Non-Cleavable Linker

By Service

  • Process / Cell-line Development
  • Analytical, Bioassay & QC
  • CGMP Conjugation & Drug-linker Manufacturing
  • Fill-finish and Packaging

By Condition

  • Haematological Malignancies
  • Solid Tumours
  • Others

By Scale of Operation

  • Clinical
  • Commercial

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East and Africa

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 20 leading companies, including:

  • AbbVie, Inc.
  • Abzena
  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Axplora
  • BSP Pharmaceuticals
  • Cambrex
  • CARBOGEN AMCIS
  • Catalent, Inc. (Novo Holdings)
  • Cerbios-Pharma SA
  • CordenPharma
  • Lonza Group AG
  • Merck KGaA
  • Oncotec Pharma Produktion GmbH
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics
  • Sterling Pharma Solutions
  • Thermo Fisher Scientific Inc. (Patheon Pharma Services)
  • WuXi XDC

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Technology roadmap and programme wins
  • Strategic outlook

Key Questions Answered

  • How is the antibody drug conjugates contract manufacturing market evolving?
  • What is driving and restraining the market?
  • How will each submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each submarket develop from 2026 to 2036?
  • Will leading national markets broadly follow macroeconomic dynamics, or will individual markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2026 and 2036?

Bespoke Intelligence and Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements. This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Supply chain and sourcing intelligence
  • High-potency containment and bioconjugation capability assessment
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

The ADC contract manufacturing market is experiencing sustained structural growth as the pipeline expands, commercial approvals accumulate, and pharmaceutical companies increase reliance on specialist CDMOs for high-potency manufacturing, bioconjugation, and integrated development-to-commercial services.

CDMOs with scalable bioconjugation infrastructure, high-potency containment capability, integrated analytical and fill-finish services, and geographically distributed manufacturing networks are best positioned to capture long-term programme value over the next decade."

Show more
Product Code: PHA1398

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Antibody Drug Conjugates Contract Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Impact Analysis
  • 3.3 Market Driving Factors
  • 3.4 Market Restraining Factors
  • 3.5 Market Opportunities
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Suppliers
    • 3.6.2 Bargaining Power of Buyers
    • 3.6.3 Competitive Rivalry
    • 3.6.4 Threat of Substitutes
    • 3.6.5 Threat of New Entrants
  • 3.7 PEST Analysis
  • 3.8 U.S. Tariffs: What's the Impact on Global Antibody Drug Conjugates Contract Manufacturing Market?
    • 3.8.1 Overview
    • 3.8.2 V-Shaped Recovery Scenario
      • 3.8.2.1 Why V-Shaped Recovery?
      • 3.8.2.2 Impact from Tariffs
      • 3.8.2.3 Market Dynamics and Demand Recovery
      • 3.8.2.4 Policy and Funding Support
      • 3.8.2.5 Timeframe for Recovery
  • 3.9 U-Shaped Recovery Scenario
      • 3.9.1.1 Why U-Shaped Recovery?
      • 3.9.1.2 Impact from Tariffs
      • 3.9.1.3 Market Dynamics and Demand Recovery
      • 3.9.1.4 Policy and Funding Support
      • 3.9.1.5 Timeframe for Recovery
  • 3.10 L Shaped Recovery Scenario
      • 3.10.1.1 Why L-Shaped Recovery?
      • 3.10.1.2 Impact from Tariffs
      • 3.10.1.3 Market Dynamics and Demand Recovery
      • 3.10.1.4 Policy and Funding Support
      • 3.10.1.5 Timeframe for Recovery
  • 3.11 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
  • 3.12 Impact of U.S. and China Trade War on Antibody Drug Conjugates Contract Manufacturing Market
  • 3.13 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?

4 Antibody Drug Conjugates Contract Manufacturing Market Analysis by Linker (US$ Million, AGR %)

  • 4.1 Key Findings
  • 4.2 Linker Segment: Market Attractiveness Index
  • 4.3 Cleavable Linker
    • 4.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.3.2 Market Share by Region, 2026 & 2036 (%)
  • 4.4 Non-Cleavable Linker
    • 4.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)

5 Antibody Drug Conjugates Contract Manufacturing Market Analysis by Service (US$ Million, AGR %)

  • 5.1 Key Findings
  • 5.2 Service Segment: Market Attractiveness Index
  • 5.3 Process / Cell-line Development
    • 5.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.3.2 Market Share by Region, 2026 & 2036 (%)
  • 5.4 Analytical, Bioassay & QC
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 CGMP Conjugation & Drug-linker Manufacturing
    • 5.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Fill-finish and Packaging
    • 5.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)

6 Antibody Drug Conjugates Contract Manufacturing Market Analysis by Condition (US$ Million, AGR %)

  • 6.1 Key Findings
  • 6.2 Condition Segment: Market Attractiveness Index
  • 6.3 Haematological Malignancies
    • 6.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.3.2 Market Share by Region, 2026 & 2036 (%)
  • 6.4 Solid Tumours
    • 6.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Others
    • 6.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Antibody Drug Conjugates Contract Manufacturing Market Analysis by Scale of Operation (US$ Million, AGR %)

  • 7.1 Key Findings
  • 7.2 Scale of Operation Segment: Market Attractiveness Index
  • 7.3 Clinical
    • 7.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.3.2 Market Share by Region, 2026 & 2036 (%)
  • 7.4 Commercial
    • 7.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)

8 Antibody Drug Conjugates Contract Manufacturing Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Antibody Drug Conjugates Contract Manufacturing Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • 9.3 North America Antibody Drug Conjugates Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 9.4 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Country
  • 9.5 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Linker
  • 9.6 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Service
  • 9.7 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Condition
  • 9.8 North America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 9.9 U.S. Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 9.10 Canada Antibody Drug Conjugates Contract Manufacturing Market Analysis

10 Europe Antibody Drug Conjugates Contract Manufacturing Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • 10.3 Europe Antibody Drug Conjugates Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Country
  • 10.5 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Linker
  • 10.6 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Service
  • 10.7 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Condition
  • 10.8 Europe Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 10.9 Germany Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 10.10 UK Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 10.11 France Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 10.12 Italy Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 10.13 Rest of Europe Antibody Drug Conjugates Contract Manufacturing Market Analysis

11 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • 11.3 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Linker
  • 11.6 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Service
  • 11.7 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Condition
  • 11.8 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 11.9 Japan Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 11.10 China Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 11.11 India Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 11.12 Australia Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 11.13 Rest of Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Analysis

12 Latin America Antibody Drug Conjugates Contract Manufacturing Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • 12.3 Latin America Antibody Drug Conjugates Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Country
  • 12.5 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Linker
  • 12.6 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Service
  • 12.7 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Condition
  • 12.8 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 12.9 Brazil Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 12.10 Mexico Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 12.11 Rest of Latin America Antibody Drug Conjugates Contract Manufacturing Market Analysis

13 MEA Antibody Drug Conjugates Contract Manufacturing Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • 13.3 MEA Antibody Drug Conjugates Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 13.4 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Country
  • 13.5 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Linker
  • 13.6 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Service
  • 13.7 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Condition
  • 13.8 MEA Antibody Drug Conjugates Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 13.9 GCC Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 13.10 South Africa Antibody Drug Conjugates Contract Manufacturing Market Analysis
  • 13.11 Rest of MEA Antibody Drug Conjugates Contract Manufacturing Market Analysis

14 Company Profiles

  • 14.1 AbbVie, Inc.
    • 14.1.1 Company Snapshot
    • 14.1.2 Company Overview
    • 14.1.3 Company Financials
      • 14.1.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.1.3.2 R&D, 2022-2025 (US$ Million)
      • 14.1.3.3 Business Segment Market Shares (%), 2025
      • 14.1.3.4 Geographic Segment Market Shares (%), 2025
    • 14.1.4 Service Benchmarking
    • 14.1.5 Strategic Outlook
  • 14.2 Abzena
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Company Financials
      • 14.2.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.2.3.2 R&D, 2022-2025 (US$ Million)
      • 14.2.3.3 Business Segment Market Shares (%), 2025
      • 14.2.3.4 Geographic Segment Market Shares (%), 2025
    • 14.2.4 Service Benchmarking
    • 14.2.5 Strategic Outlook
  • 14.3 AGC Biologics
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Company Financials
      • 14.3.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.3.3.2 R&D, 2022-2025 (US$ Million)
      • 14.3.3.3 Business Segment Market Shares (%), 2025
      • 14.3.3.4 Geographic Segment Market Shares (%), 2025
    • 14.3.4 Service Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Ajinomoto Bio-Pharma Services
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Company Financials
      • 14.4.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.4.3.2 R&D, 2022-2025 (US$ Million)
      • 14.4.3.3 Business Segment Market Shares (%), 2025
      • 14.4.3.4 Geographic Segment Market Shares (%), 2025
    • 14.4.4 Service Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Axplora
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Company Financials
      • 14.5.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.5.3.2 R&D, 2022-2025 (US$ Million)
      • 14.5.3.3 Business Segment Market Shares (%), 2025
      • 14.5.3.4 Geographic Segment Market Shares (%), 2025
    • 14.5.4 Service Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 BSP Pharmaceuticals
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Company Financials
      • 14.6.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.6.3.2 R&D, 2022-2025 (US$ Million)
      • 14.6.3.3 Business Segment Market Shares (%), 2025
      • 14.6.3.4 Geographic Segment Market Shares (%), 2025
    • 14.6.4 Service Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Cambrex
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Company Financials
      • 14.7.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.7.3.2 R&D, 2022-2025 (US$ Million)
      • 14.7.3.3 Business Segment Market Shares (%), 2025
      • 14.7.3.4 Geographic Segment Market Shares (%), 2025
    • 14.7.4 Service Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 CARBOGEN AMCIS
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Company Financials
      • 14.8.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.8.3.2 R&D, 2022-2025 (US$ Million)
      • 14.8.3.3 Business Segment Market Shares (%), 2025
      • 14.8.3.4 Geographic Segment Market Shares (%), 2025
    • 14.8.4 Service Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Catalent, Inc. (Novo Holdings)
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Company Financials
      • 14.9.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.9.3.2 R&D, 2022-2025 (US$ Million)
      • 14.9.3.3 Business Segment Market Shares (%), 2025
      • 14.9.3.4 Geographic Segment Market Shares (%), 2025
    • 14.9.4 Service Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Cerbios-Pharma SA
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Company Financials
      • 14.10.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.10.3.2 R&D, 2022-2025 (US$ Million)
      • 14.10.3.3 Business Segment Market Shares (%), 2025
      • 14.10.3.4 Geographic Segment Market Shares (%), 2025
    • 14.10.4 Service Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 CordenPharma
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Company Financials
      • 14.11.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.11.3.2 R&D, 2022-2025 (US$ Million)
      • 14.11.3.3 Business Segment Market Shares (%), 2025
      • 14.11.3.4 Geographic Segment Market Shares (%), 2025
    • 14.11.4 Service Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 Lonza Group AG
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Company Financials
      • 14.12.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.12.3.2 R&D, 2022-2025 (US$ Million)
      • 14.12.3.3 Business Segment Market Shares (%), 2025
      • 14.12.3.4 Geographic Segment Market Shares (%), 2025
    • 14.12.4 Service Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Merck KGaA
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Company Financials
      • 14.13.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.13.3.2 R&D, 2022-2025 (US$ Million)
      • 14.13.3.3 Business Segment Market Shares (%), 2025
      • 14.13.3.4 Geographic Segment Market Shares (%), 2025
    • 14.13.4 Service Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Oncotec Pharma Produktion GmbH
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Company Financials
      • 14.14.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.14.3.2 R&D, 2022-2025 (US$ Million)
      • 14.14.3.3 Business Segment Market Shares (%), 2025
      • 14.14.3.4 Geographic Segment Market Shares (%), 2025
    • 14.14.4 Service Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Piramal Pharma Solutions
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Company Financials
      • 14.15.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.15.3.2 R&D, 2022-2025 (US$ Million)
      • 14.15.3.3 Business Segment Market Shares (%), 2025
      • 14.15.3.4 Geographic Segment Market Shares (%), 2025
    • 14.15.4 Service Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Recipharm AB
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Company Financials
      • 14.16.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.16.3.2 R&D, 2022-2025 (US$ Million)
      • 14.16.3.3 Business Segment Market Shares (%), 2025
      • 14.16.3.4 Geographic Segment Market Shares (%), 2025
    • 14.16.4 Service Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 Samsung Biologics
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Company Financials
      • 14.17.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.17.3.2 R&D, 2022-2025 (US$ Million)
      • 14.17.3.3 Business Segment Market Shares (%), 2025
      • 14.17.3.4 Geographic Segment Market Shares (%), 2025
    • 14.17.4 Service Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Sterling Pharma Solutions
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Company Financials
      • 14.18.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.18.3.2 R&D, 2022-2025 (US$ Million)
      • 14.18.3.3 Business Segment Market Shares (%), 2025
      • 14.18.3.4 Geographic Segment Market Shares (%), 2025
    • 14.18.4 Service Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Thermo Fisher Scientific Inc. (Patheon Pharma Services)
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Company Financials
      • 14.19.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.19.3.2 R&D, 2022-2025 (US$ Million)
      • 14.19.3.3 Business Segment Market Shares (%), 2025
      • 14.19.3.4 Geographic Segment Market Shares (%), 2025
    • 14.19.4 Service Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 WuXi XDC
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Company Financials
      • 14.20.3.1 Revenue, 2022-2025 (US$ Million)
      • 14.20.3.2 R&D, 2022-2025 (US$ Million)
      • 14.20.3.3 Business Segment Market Shares (%), 2025
      • 14.20.3.4 Geographic Segment Market Shares (%), 2025
    • 14.20.4 Service Benchmarking
    • 14.20.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Player
Show more
Product Code: PHA1398

List of Tables

  • Table 1 Antibody Drug Conjugates Contract Manufacturing Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
  • Table 2 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 3 Cleavable Linker Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 4 Non-Cleavable Linker Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 5 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 6 Process / Cell-line Development Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 7 Analytical, Bioassay & QC Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 8 CGMP Conjugation & Drug-linker Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 9 Fill-finish and Packaging Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 10 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 11 Haematological Malignancies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 12 Solid Tumours Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 13 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 14 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 15 Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 16 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 17 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 18 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 19 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 20 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 21 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 22 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 23 U.S. Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 24 Canada Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 25 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 26 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 27 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 28 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 29 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 30 Germany Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 31 UK Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 32 France Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 33 Italy Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 34 Rest of Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 35 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 36 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 37 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 38 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 39 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 40 Japan Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 41 China Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 42 India Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 43 Australia Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 44 Rest of Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 45 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 46 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 47 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 48 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 49 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 50 Brazil Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 51 Mexico Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 52 Argentina Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 53 Colombia Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 54 Rest of Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 55 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 56 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 57 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 58 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 59 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 60 GCC Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 61 South Africa Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 62 Rest of MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 63 AbbVie, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 64 AbbVie, Inc.: Service Benchmarking
  • Table 65 AbbVie, Inc.: Strategic Outlook
  • Table 66 Abzena: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 67 Abzena: Service Benchmarking
  • Table 68 Abzena: Strategic Outlook
  • Table 69 AGC Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 70 AGC Biologics: Service Benchmarking
  • Table 71 AGC Biologics: Strategic Outlook
  • Table 72 Ajinomoto Bio-Pharma Services: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 Ajinomoto Bio-Pharma Services: Service Benchmarking
  • Table 74 Ajinomoto Bio-Pharma Services: Strategic Outlook
  • Table 75 Axplora: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 Axplora: Service Benchmarking
  • Table 77 Axplora: Strategic Outlook
  • Table 78 BSP Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 BSP Pharmaceuticals: Service Benchmarking
  • Table 80 BSP Pharmaceuticals: Strategic Outlook
  • Table 81 Cambrex: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Cambrex: Service Benchmarking
  • Table 83 Cambrex: Strategic Outlook
  • Table 84 CARBOGEN AMCIS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 CARBOGEN AMCIS: Service Benchmarking
  • Table 86 CARBOGEN AMCIS: Strategic Outlook
  • Table 87 Catalent, Inc. (Novo Holdings): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Catalent, Inc. (Novo Holdings): Service Benchmarking
  • Table 89 Catalent, Inc. (Novo Holdings): Strategic Outlook
  • Table 90 Cerbios-Pharma SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Cerbios-Pharma SA: Service Benchmarking
  • Table 92 Cerbios-Pharma SA: Strategic Outlook
  • Table 93 CordenPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 CordenPharma: Service Benchmarking
  • Table 95 CordenPharma: Strategic Outlook
  • Table 96 Lonza Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Lonza Group AG: Service Benchmarking
  • Table 98 Lonza Group AG: Strategic Outlook
  • Table 99 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Merck KGaA: Service Benchmarking
  • Table 101 Merck KGaA: Strategic Outlook
  • Table 102 Oncotec Pharma Produktion GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Oncotec Pharma Produktion GmbH: Service Benchmarking
  • Table 104 Oncotec Pharma Produktion GmbH: Strategic Outlook
  • Table 105 Piramal Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Piramal Pharma Solutions: Service Benchmarking
  • Table 107 Piramal Pharma Solutions: Strategic Outlook
  • Table 108 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 Recipharm AB: Service Benchmarking
  • Table 110 Recipharm AB: Strategic Outlook
  • Table 111 Samsung Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Samsung Biologics: Service Benchmarking
  • Table 113 Samsung Biologics: Strategic Outlook
  • Table 114 Sterling Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Sterling Pharma Solutions: Service Benchmarking
  • Table 116 Sterling Pharma Solutions: Strategic Outlook
  • Table 117 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Service Benchmarking
  • Table 119 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Strategic Outlook
  • Table 120 WuXi XDC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 WuXi XDC: Service Benchmarking
  • Table 122 WuXi XDC: Strategic Outlook

List of Figures

  • Figure 1 Antibody Drug Conjugates Contract Manufacturing Market Segmentation
  • Figure 2 Antibody Drug Conjugates Contract Manufacturing Market by Linker: Market Attractiveness Index
  • Figure 3 Antibody Drug Conjugates Contract Manufacturing Market by Service: Market Attractiveness Index
  • Figure 4 Antibody Drug Conjugates Contract Manufacturing Market by Condition: Market Attractiveness Index
  • Figure 5 Antibody Drug Conjugates Contract Manufacturing Market by Scale of Operation: Market Attractiveness Index
  • Figure 6 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index by Region
  • Figure 7 Antibody Drug Conjugates Contract Manufacturing Market: Market Dynamics
  • Figure 8 Antibody Drug Conjugates Contract Manufacturing Market: Porter's Five Forces Analysis
  • Figure 9 Antibody Drug Conjugates Contract Manufacturing Market: PEST Analysis
  • Figure 10 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index by Linker
  • Figure 11 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %)
  • Figure 12 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast by Linker, 2026, 2031, 2036 (%)
  • Figure 13 Cleavable Linker Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 14 Cleavable Linker Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 15 Non-Cleavable Linker Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 16 Non-Cleavable Linker Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 17 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index by Service
  • Figure 18 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %)
  • Figure 19 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast by Service, 2026, 2031, 2036 (%)
  • Figure 20 Process / Cell-line Development Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 21 Process / Cell-line Development Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 22 Analytical, Bioassay & QC Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 23 Analytical, Bioassay & QC Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 24 CGMP Conjugation & Drug-linker Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 25 CGMP Conjugation & Drug-linker Manufacturing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 26 Fill-finish and Packaging Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 27 Fill-finish and Packaging Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 28 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index by Condition
  • Figure 29 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %)
  • Figure 30 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast by Condition, 2026, 2031, 2036 (%)
  • Figure 31 Haematological Malignancies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 32 Haematological Malignancies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 33 Solid Tumours Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 34 Solid Tumours Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 35 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 36 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 37 Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index by Scale of Operation
  • Figure 38 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 39 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 40 Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 41 Clinical Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 42 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 43 Commercial Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 44 Antibody Drug Conjugates Contract Manufacturing Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
  • Figure 45 Antibody Drug Conjugates Contract Manufacturing Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 46 Antibody Drug Conjugates Contract Manufacturing Market by Region, 2026-2036 (US$ Bn, AGR %)
  • Figure 47 North America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • Figure 48 North America Antibody Drug Conjugates Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 49 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 50 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %)
  • Figure 51 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %)
  • Figure 52 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %)
  • Figure 53 North America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 54 U.S. Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 55 Canada Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 56 Europe Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • Figure 57 Europe Antibody Drug Conjugates Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 58 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 59 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %)
  • Figure 60 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %)
  • Figure 61 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %)
  • Figure 62 Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 63 Germany Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 64 UK Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 65 France Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 66 Italy Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 67 Rest of Europe Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 68 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • Figure 69 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 70 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 71 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %)
  • Figure 72 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %)
  • Figure 73 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %)
  • Figure 74 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 75 Japan Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 76 China Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 77 India Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 78 Australia Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 79 Rest of Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 80 Latin America Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • Figure 81 Latin America Antibody Drug Conjugates Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 82 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 83 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %)
  • Figure 84 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %)
  • Figure 85 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %)
  • Figure 86 Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 87 Brazil Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 88 Mexico Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 89 Rest of Latin America Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 90 MEA Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Index
  • Figure 91 MEA Antibody Drug Conjugates Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 92 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 93 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Linker, 2026-2036 (US$ Million, AGR %)
  • Figure 94 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Service, 2026-2036 (US$ Million, AGR %)
  • Figure 95 MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast by Condition, 2026-2036 (US$ Million, AGR %)
  • Figure 96 GCC Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 97 South Africa Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 98 Rest of MEA Antibody Drug Conjugates Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 99 AbbVie, Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 100 AbbVie, Inc.: Regional Market Shares (%), 2025
  • Figure 101 AbbVie, Inc.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 102 Abzena: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 103 Abzena: Regional Market Shares (%), 2025
  • Figure 104 Abzena: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 105 AGC Biologics: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 106 AGC Biologics: Regional Market Shares (%), 2025
  • Figure 107 AGC Biologics: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 108 Ajinomoto Bio-Pharma Services: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 109 Ajinomoto Bio-Pharma Services: Regional Market Shares (%), 2025
  • Figure 110 Ajinomoto Bio-Pharma Services: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 111 Axplora: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 112 Axplora: Regional Market Shares (%), 2025
  • Figure 113 Axplora: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 114 BSP Pharmaceuticals: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 115 BSP Pharmaceuticals: Regional Market Shares (%), 2025
  • Figure 116 BSP Pharmaceuticals: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 117 Cambrex: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 118 Cambrex: Regional Market Shares (%), 2025
  • Figure 119 Cambrex: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 120 CARBOGEN AMCIS: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 121 CARBOGEN AMCIS: Regional Market Shares (%), 2025
  • Figure 122 CARBOGEN AMCIS: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 123 Catalent, Inc. (Novo Holdings): Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 124 Catalent, Inc. (Novo Holdings): Regional Market Shares (%), 2025
  • Figure 125 Catalent, Inc. (Novo Holdings): R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 126 Cerbios-Pharma SA: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 127 Cerbios-Pharma SA: Regional Market Shares (%), 2025
  • Figure 128 Cerbios-Pharma SA: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 129 CordenPharma: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 130 CordenPharma: Regional Market Shares (%), 2025
  • Figure 131 CordenPharma: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 132 Lonza Group AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 133 Lonza Group AG: Regional Market Shares (%), 2025
  • Figure 134 Lonza Group AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 135 Merck KGaA: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 136 Merck KGaA: Regional Market Shares (%), 2025
  • Figure 137 Merck KGaA: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 138 Oncotec Pharma Produktion GmbH: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 139 Oncotec Pharma Produktion GmbH: Regional Market Shares (%), 2025
  • Figure 140 Oncotec Pharma Produktion GmbH: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 141 Piramal Pharma Solutions: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 142 Piramal Pharma Solutions: Regional Market Shares (%), 2025
  • Figure 143 Piramal Pharma Solutions: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 144 Recipharm AB: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 145 Recipharm AB: Regional Market Shares (%), 2025
  • Figure 146 Recipharm AB: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 147 Samsung Biologics: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 148 Samsung Biologics: Regional Market Shares (%), 2025
  • Figure 149 Samsung Biologics: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 150 Sterling Pharma Solutions: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 151 Sterling Pharma Solutions: Regional Market Shares (%), 2025
  • Figure 152 Sterling Pharma Solutions: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 153 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 154 Thermo Fisher Scientific Inc. (Patheon Pharma Services): Regional Market Shares (%), 2025
  • Figure 155 Thermo Fisher Scientific Inc. (Patheon Pharma Services): R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 156 WuXi XDC: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 157 WuXi XDC: Regional Market Shares (%), 2025
  • Figure 158 WuXi XDC: R&D, 2022-2025 (US$ Million, AGR %)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!